2025-521603-46-00
Not yet recruiting
Phase 1
A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:01 and a tumour protein called PRAME.
Overview
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- T-Knife GmbH
- Enrollment
- 24
- Locations
- 3
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Michael Loveridge
Scientific
T-Knife GmbH
Study Sites (3)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
A phase I of TG6050 in the treatment of patients with metastatic lung cancer2024-513093-22-00Transgene36
Completed
Phase 1
Study to Evaluate the Safety and Efficacy of Treatment with NLM-001 before Standard Chemotherapy plus Zalifrelimab in Patients with Advanced Pancreatic Cancer2024-518852-22-00Nelum Corp.28
Recruiting
Phase 1
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors2024-513285-19-00Kura Oncology Inc.68
Not yet recruiting
Phase 1
A Phase 1 study of GSK5764227 in participants with advanced solid tumors2024-513663-10-01Glaxosmithkline Research & Development Limited, Glaxosmithkline Research & Development Limited112
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaNCT07323654Kymera Therapeutics, Inc.264